Europe needs to refocus its drug anti-counterfeiting measures
This article was originally published in Scrip
Counterfeit medicines have been big news in Europe over the past two months. The pharmaceutical industry, the World Health Organization and the European Parliament have been vociferously expounding on the success and progress of various initiatives aimed at preventing the emergence of fake medicinal products in the legitimate supply chain. These are welcome and laudable actions, aimed at protecting human health, but are they focusing on the right target?